NEW YORK (GenomeWeb News) – Sirius Genomics and Golden Helix today announced a collaboration to develop companion diagnostics directed at septic shock and related conditions.
Under the deal, the two firms will develop diagnostics to identify individuals who respond well to Vasopressin and other compounds for the treatment of septic shock. The partnership combines Golden Helix technologies and expertise in SNP and copy number variant analysis and predictive modeling with Sirius experience in diagnostics development.
Terms of the deal were not disclosed.
According to Chris Wagner, president and CEO of Sirius, Golden Helix will provide his firm access to expertise in genome-wide association studies analysis and bioinformatics capabilities. Combined with recent funding Sirius has received from the National Research Council of Canada, the partnership with Golden Helix "enables us to focus our strengths in discovery and development on our pipeline of companion diagnostic programs and focus on improving outcomes in critical care medicine," Wagner said in a joint statement issued from Sirius, based in Vancouver, British Columbia, and Golden Helix, headquartered in Bozeman, Mont.
Citing statistics from the US Centers for Disease Control and Prevention, the two firms said that septic shock is the 13th leading cause of death in the US and the leading cause of death in intensive care units. The standard of care for addressing septic shock is intravenous norepinephrine, but the mortality rate remains at about 50 percent, the companies said.